NCT01389609

Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: Male
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To test bioequivalence of Doxazosin 4 Mg Orally-disintegrating Tablet with Or Without Water to Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Doxazosin 4 mg Japanese marketed IR tablet	Immediate release tablet, 4 mg, single dose
DRUG	Doxazosin 4 mg ODT with water	Orally-disintegrating Tablet , 4 mg, single dose with water
DRUG	Doxazosin 4 mg ODT without water	Orally-disintegrating Tablet , 4 mg, single dose without water

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2011-07-08
• Last updated: 2021-01-29

Locations

1 site across 1 country: Japan